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PREVENTION AND INFECTION CONTROL FOR NOROVIRAL INFECTION
Cheng-Hsun Chiu, MD, PhD. Division of Pediatric Infectious Diseases, Chang
Gung Children’s Hospital, Chang Gung University College of Medicine,
Taoyuan, Taiwan
Norovirus, a genus within the Caliciviridae family, is the leading cause of
sporadic and epidemic acute gastroenteritis worldwide. Our understanding
of norovirus epidemiology has significantly progressed in recent years due
to the development of sensitive molecular diagnostic techniques. We now
understand that human noroviruses are extremely diverse, with three gen-
ogroups (GI, GII, and GIV), at least 25 genotypes, and numerous subgeno-
types or variants identified in the past two decades. In recent years, only
a few strains, primarily those of genogroup II, genotype 4 (GII.4) have
been responsible for the majority of outbreaks. Norovirus genotype GII.4 is
responsible for the majority of outbreaks, but new variants are continuously
emerging. Noroviruses are found in the feces and vomit of infected people.
This virus is very contagious and can spread rapidly throughout healthcare
facilities. People can become infected with the virus in several ways: 1) Hav-
ing direct contact with another person who is infected; 2) Eating food or
drinking liquids or water that are contaminated with norovirus; 3) Touching
surfaces or objects contaminated with norovirus, and then touching your
mouth or other food items. In a healthcare facility, patients with suspected
norovirus may be placed in private rooms or share rooms with other patients
with the same infection. Additional prevention measures in healthcare facil-
ities can decrease the chance of coming in contact with noroviruses: 1)
Follow hand-hygiene guidelines, and carefully washing of hands with soap
and water after contact with patients with norovirus infection; 2) Use gowns
and gloves when in contact with, or caring for patients who are symptomatic
with norovirus; 3) Routinely clean and disinfect high touch patient surfaces
and equipment with an authority-approved product with a label claim for
norovirus; 4) Remove and wash contaminated clothing or linens; and 5)
Healthcare workers who have symptoms consistent with norovirus should
be excluded from work. A norovirus vaccine is being developed for active
prevention of the infection in children as well as in adults.SYMPOSIUM 5 (SP 5)
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INFECTIONS CAUSED BY RARE FUNGI
Jacques F. Meis. Department of Medical Microbiology and Infectious
Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands;
Department of Medical Microbiology, Radboud University Medical Center,
Nijmegen, The Netherlands
The predominant nosocomial fungal pathogens are Candida spp., and
Aspergillus spp. but rare and emerging fungi are increasingly being reported,
also among Candida and Aspergillus genera and species complexes. These
rare pathogens are mostly seen in severely immunocompromised hosts. The
presentation will focus on Cryptococcus gattii, newly recognized yeast spp,
black yeasts, Exserohilum, and Penicillium spp. Rapid taxonomic changes are
a hallmark of these fungi. Especially for epidemiological purposes, including
outbreak investigation, molecular identification is indispensible. Rare fungal
pathogens are often resistant to one or more antifungal drugs.SP 5-2
CURRENT MANAGEMENT OF CHRONIC HEPATITIS C
Owen Tak Yin Tsang. Infectious Disease Centre, Princess Margaret Hospital,
Hong Kong Special Administrative Region
Chronic hepatitis C is a global disease. An estimated of 150 millions people
worldwide are chronically infected and around 350,000 to 500,000 people
die each year from hepatitis C related liver diseases. Around 15% to 30% of
patients with chronic hepatitis C will develop cirrhosis in 20 years. The risk
of development of hepatocellular carcinoma would be about 1e4% per yearonce the patient has progressed to cirrhosis. The prevalence of chronic
hepatitis C is the highest in Asia Pacific region. It varies from 1% in Southeast
Asia to 5.4% in Central Asia. Chronic hepatitis C also accounts for a
significant proportion of patients requiring liver transplantation as a result
of decompensation or development of hepatocellular carcinoma. There are
altogether 6 genotypes of hepatitis C worldwide and genotype 1 is most
common of all infections, followed by genotypes 2 & 3. Genotype 6a is
particularly prevalent in Southeast Asia, accounting for over 50% in countries
like Cambodia or Vietnam. This genotype is also exclusively common in
intravenous drug abusers. The management of chronic hepatitis C has
evolved extensively over the years. Combination therapy with pegylated
Interferon and ribavirin has been the standard of care for more than 10
years. An over 80% sustain virological response rate (SVR) can be achieved
for patients infected with genotype 2 and 3 after half year treatment of this
regime. However, the SVR for genotype 1 after this combo can only fall
around 50% even with 48 weeks of therapy. Moreover, significant side effects
from the combination including flu-like symptoms, fever, myalgia, malaise,
cough, allergic reactions, cytopenia, thyroid diseases, alopecia or insomnia
can be anticipated. In response to these caveats, researchers has devoted to
develop new antivirals targeting directly on the virus itself, so called the
Direct-acting Antivirals (DAAs), with an aim of increasing efficacy and
enhancing tolerability & safety. The first generation DAAs include boceprevir
and telaprevir. When these medications are used in combination with the
pegylated interferon and ribavirin, a 10e20% increase in SVR can be
achieved in genotype 1-treatment naı¨ve patients. SVR in difficult-to-treat
patients such as previous non-responders to dual therapy is still disap-
pointing. Moreover, the added side effects including aggravation of anemia,
dysguesia and enhanced allergic reaction can be difficult to overcome.
Interferon-free regime is then a very attractive strategy of therapy.
Sofosbuvir is the first compound ever produced to be the interferon-free
treatment. When it is combined with other antivirals for different geno-
types, an extraordinary SVR of 80% to even over 90% can be attained. The
rapid development of hepatitis C medications is unprecedented. There are
at least 10 novel medications on the pipeline to enter this treatment arena.
The future eradication of hepatitis C virus may be anticipated.SP 5-3
CURRENT MANAGEMENT OF HIV INFECTION
Chien-Ching Hung. National Taiwan University College of Medicine, Taipei,
Taiwan
No abstract.
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NATIONAL IMPLEMENTATION OF ANTIMICROBIAL STEWARDSHIP
PROGRAMS
Marilyn Cruickshank. Faculty of Nursing and Midwifery, Griffith University,
Queensland, Australia
A snap shot survey conducted in 2008 of AMS programs in Australian hospitals
reported only 11% of hospitals had a fully integrated AMS program in place
that was overseen by a central body or committee; only 67% used guidelines
to guide antimicrobial prescribing, and only 47% did regular audits of
antimicrobial prescribing (Chen 2011).
The National Safety and Quality Health Service (NSQHS) Standards were
designed to protect the public from harm and to improve the quality of care
to patients. In implementing the NSQHS Standards, health services have put
in place safety and quality systems to ensure standards of care are met and
quality improvement mechanisms exist. This includes the implementation of
Antimicrobial Stewardship (AMS) programs in every hospital and day proce-
dure service in Australia.
Since the implementation of Standard 3, 100% of health services accredited
to date have a fully developed AMS program, all prescribers have access to
antibiotic guidelines, and, all health services monitor their use of antibiotics.
While some countries have developed guidelines and strategies for AMS
program, many are yet to include specific requirements for the management
of antibiotic resistance and usage Australia leads the world in mandated
requirements for infection prevention and control and AMS in health services
